BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.590
+0.040 (2.58%)
Dec 20, 2024, 4:00 PM EST - Market closed
BeyondSpring Revenue
BeyondSpring had revenue of $1.00M in the half year ending June 30, 2024, with 47.93% growth. This brings the company's revenue in the last twelve months to $1.88M, up 21.03% year-over-year. In the year 2023, BeyondSpring had annual revenue of $1.75M with 29.61% growth.
Revenue (ttm)
$1.88M
Revenue Growth
+21.03%
P/S Ratio
33.09
Revenue / Employee
$52,111
Employees
36
Market Cap
64.08M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Burning Rock Biotech | 72.83M |
Forian | 19.71M |
Verrica Pharmaceuticals | 9.21M |
Milestone Scientific | 8.88M |
IceCure Medical | 3.67M |
Vistagen Therapeutics | 876.00K |
BYSI News
- 5 weeks ago - BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting - GlobeNewsWire
- 2 months ago - BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus
- 3 months ago - BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - GlobeNewsWire
- 3 months ago - BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - GlobeNewsWire
- 3 months ago - BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - GlobeNewsWire
- 4 months ago - SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications - GlobeNewsWire
- 7 months ago - BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics - GlobeNewsWire
- 8 months ago - BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics - GlobeNewsWire